trending Market Intelligence /marketintelligence/en/news-insights/trending/zkj2a9leg8wgx-3-lkxiza2 content esgSubNav
In This List

Israel's Galmed plans $75M ordinary shares offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Israel's Galmed plans $75M ordinary shares offering

Galmed Pharmaceuticals Ltd. is planning an offering of ordinary shares to raise about $75 million in gross proceeds.

The Israeli company intends to grant the underwriters an option to buy up to an additional 15% of the shares sold in the offering.

Galmed intends to use the net proceeds for the continued development of Aramchol to treat nonalcoholic steatohepatitis, or NASH — the most severe form of nonalcoholic fatty liver disease; for developing new programs; for business development activities and for general corporate purposes.

Stifel, SunTrust Robinson Humphrey and Cantor Fitzgerald are acting as book-running managers, while Raymond James and Roth Capital Partners are serving as co-lead managers for the offering. Maxim Group LLC and Seaport Global Securities are acting as co-managers for the offering.